Distribution and metabolism of intravenously administered trefoil factor 2/porcine spasmolytic polypeptide in the rat

S S Poulsen, J Thulesen, E Nexø, L Thim

Abstract

Background—Trefoil peptides are secreted by mucus producing cells in the gastrointestinal tract and are supposed to be involved in oligomerisation processes of the mucin glycoproteins in the lumen. Endocrine functions have also been suggested.

Aims—To target possible binding sites for iodine-125 labelled porcine spasmolytic polypeptide (pSP) in an in vivo rat model.

Methods—125I-pSP was given by intravenous injection to female Spraque-Dawley rats. The distribution of 125I-pSP was assessed by gamma counting of samples of organs and by autoradiography of paraffin wax embedded sections. The degradation of 125I-pSP was studied by trichloroacetic acid precipitation, and the saturability of binding by administration of excess unlabelled peptide.

Results—125I-pSP was taken up in the kidneys and the gastrointestinal tract and was excreted almost unmetabolised in the urine. In the stomach, it could be displaced by unlabelled pSP in a dose dependent manner. Autoradiography showed grains in mucous neck cells, parietal cells, the mucus layer, and the pyloric glands of the stomach; in Brunner’s glands and the Paneth cells in the small intestine; and in cells in the lower part of the crypts in the colon. The binding can be displaced by non-radioactive pSP, suggesting the presence of a receptor.

Conclusions—125I-pSP from the circulatory system is taken up by mucus producing cells in the gastrointestinal tract. The binding can be displaced by non-radioactive pSP, suggesting the presence of a receptor.

Keywords: trefoil peptides; trefoil factor 2; spasmolytic polypeptide; metabolism; autoradiography; rat

Porcine spasmolytic polypeptide (pSP) belongs to a family of mucin associated gastrointestinal peptides. These peptides have been named trefoil factors (TFF) due to the existence of one or more domains in which six cysteine residues form three disulphide bonds to create a characteristic three leaved structure. In addition to SP (also named TFF2) the mammalian trefoil factor family also includes the breast cancer associated peptide, pS2 (also named TFF1) and intestinal trefoil factor, ITF (also named TFF3). Porcine SP was originally isolated from the pancreas. By immunohistochemical investigations, the peptide was localised to exocrine cells of the stomach, duodenum, and pancreas. Homologous peptides to porcine SP have been identified in other species. The trefoil peptide family now includes SP from pig, rat, mouse, and man, which is secreted from the pyloric glands, the mucous neck cells of the corpus fundic glands, and the duodenal Brunner glands; ITF from rat, mouse, and man secreted from the intestinal goblet cells; and the pS2 peptide shown in the surface epithelium of the stomach from man and mouse (for review see Thim). The physiological role of the trefoil peptides is not yet fully elucidated. The presence of the peptides in exocrine cells in the gastrointestinal tract suggests a function in the gastrointestinal secretions. They are highly resistant to degradation by proteases, probably due to their compact three dimensional structure. They are secreted by mucus producing cells, and in the lumen they are supposed to link together the polysaccharide sidechains of mucin glycoproteins to form large, highly viscous, and resistant complexes.

In accordance with this, mice with a non-functional gene encoding ITF have impaired mucosal healing in the colon; transgenic mice that overexpress pS2 have increased resistance to mucosal damage; and pretreatment of rats with oral SP or ITF has been shown to protect against gastric injury.

Endocrine functions of the trefoil peptides have also been suggested. The first reports on the effects of pSP described an inhibitory effect on intestinal motility and on gastric acid secretion, and relaxation of the sphincter Oddi. Small amounts of SP are present in plasma from the pig and receptor-like binding sites have been suggested from in vitro investigations on rat intestinal mucosal cell membranes for SP and on frozen sections from rat gastrointestinal tissues for ITF.

Moreover, mice with inactivated pS2 gene developed malignant transformation in the stomach. Recently, it was shown that subcutaneous injections of SP in very low doses to rats protected against indomethacin induced gastric damage without inhibiting acid secretion, whereas similar doses of oral SP were without any effect. The effect of pSP was proposed to be mediated by increased cell migration, an effect which has now been shown in vitro for all three trefoil factors.

In order to target possible binding sites for circulating SP in an vivo model, we have studied

Institute of Medical Anatomy, University of Copenhagen, The Panum Institute, Copenhagen S S Poulsen J Thulesen

Department of Clinical Biochemistry, Århus University Hospital, Århus E Nexø

Department of Protein Chemistry, Novo Nordisk A/S, Copenhagen, Denmark L Thim

Correspondence to: Dr S S Poulsen, Institute of Medical Anatomy B, University of Copenhagen, The Panum Institute, 3 Blegdamsvej, 2200 Copenhagen N, Denmark.

Accepted for publication 18 February 1998

the distribution and metabolism of intravenously administered iodine-125 labelled pSP in the rat.

**Materials and methods**

**PREPARATION OF 125I-pSP**

pSP 100 µg, highly purified as previously described, was iodinated by Amersham International (UK), with sodium 125I-iodide, using hydrogen peroxide and lactoperoxidase. The specific activity obtained was 222 kBq/µg (6 µCi/µg). The iodinated peptide was diluted to a radioactive concentration of 100 µCi/ml with 5% lactose, 0.25% radioimmunoassay (RIA) grade bovine serum albumin, and 0.3 trypsin inhibitor units/ml aprotinin, in 50 mM sodium phosphate buffer, pH 7.4. Before use 125I-pSP was diluted in 0.154 mmol/l saline with 1% bovine serum albumin to a final concentration of 0.5 µg/ml (approximately 1 × 10⁶ cpm/ml).

**TISSUE DISTRIBUTION OF 125I-pSP**

The animal studies were approved by the Danish National Committee for Animal Studies. For quantitative studies on the distribution of 125I-pSP, 28 female Spraque-Dawley rats, weighing 250–270 g, were anaesthetised by an intraperitoneal injection of 50 mg/kg methohexitol (Brietal, Lilly, USA); buprenorphine (Temgesic, Reckitt and Colman Pharmaceuticals, Hull, UK) 0.1 mg/kg subcutaneously was given as an analgesic. The abdomen was opened by a midline incision and 950 µl of 125I-pSP was injected into the inferior vena cava. A sample of 50 µl was counted with a gamma spectrometer in order to estimate the counts given to each rat. The rats were sacrificed in groups of four after 2, 6, 15, 45, 120, and 240 minutes, and 24 hours. In the first three groups, the rats did not regain consciousness before sacrifice, whereas the rats sacrificed after 45, 120, and 240 minutes and 24 hours had the midline incision sutured and were reanaesthetised before sacrifice. For collection of urine, the rats had the urethra ligated and the bladder was emptied by cannulation at sacrifice. The 24 hour rats were placed in Bollman cages for collection of urine. When sacrificed, the rats were connected to an animal respirator (Harvard Apparatus, Massachusetts, USA) and the thorax was opened. Blood (1 ml) was drawn from the right cardiac ventricle and urine was collected from the bladder. The vascular system was then perfused through the left cardiac ventricle (outlet through the right atrium) with 150 ml saline to ensure removal of blood from the organs. The effluent was collected. The organs were removed and weighed and samples of the organs with known weight, a sample of blood, a sample of the effluent saline, and the 50 ml sample of the 125I-pSP injected into each rat were counted in a gamma spectrometer (Wallach, LKB, UK).

To investigate whether the metabolism of pSP is influenced by the dose given and the binding of pSP is saturable, 0.05 mg, 1 mg, or 10 mg unlabelled pSP was given together with 125I-pSP to three rats for each dose. The rats were sacrificed after 15 minutes. Tissues investigated were liver, pancreas, oesophagus, the various parts of the stomach, the duodenum, jejunum, ileum, caecum, colon, submandibular gland, lung, brain, heart, adipose tissue, skeletal muscle, uterus, ovary, kidney, urinary bladder, adrenal gland, thyroid gland, and skin. The radioactivity was calculated as the percentage of the total radioactivity administered to each rat present in each organ or as the percentage of total radioactivity per gram tissue in each organ.

**AUTORADIOGRAPHY**

After perfusion with saline (see above) two rats in each group (0, 2, 6, 15, 45, 120, and 240 minutes) were fixed by perfusion for two minutes with ice cold freshly prepared 4% glutaraldehyde in 0.04 mol/l phosphate buffer, pH 7.4. The same tissues as described above were investigated. The tissues were removed and postfixed for 24 hours in 70% ethanol, dehydrated, and embedded in paraffin wax. Histological sections of 5 µm were coated with Ilford K2 liquid autoradiographic emulsion diluted 1/1 in 300 mM ammonium acetate, placed in light tight boxes, and stored at −80°C for four or seven weeks. The autoradiographs were developed in an Ilford developer for five minutes at 17°C and fixed in Kodak fixer for five minutes. The sections were stained slightly with haematoxylin and examined by light microscopy.

---

**Table 1** Distribution of percentage radioactivity after injection of 125I-pSP over time

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Time (min)</th>
<th>2</th>
<th>6</th>
<th>15</th>
<th>45</th>
<th>240</th>
<th>24 hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood</td>
<td></td>
<td>51(6)</td>
<td>23(7)</td>
<td>19(9)</td>
<td>4(1)</td>
<td>5(1)</td>
<td>2(1)</td>
</tr>
<tr>
<td>Gastrointestinal tract</td>
<td></td>
<td>9(3)</td>
<td>14(5)</td>
<td>12(5)</td>
<td>8(2)</td>
<td>9(1)</td>
<td>3(1)</td>
</tr>
<tr>
<td>Kidney</td>
<td></td>
<td>16(8)</td>
<td>40(10)</td>
<td>28(13)</td>
<td>23(9)</td>
<td>3(1)</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Urine</td>
<td></td>
<td>15(7)</td>
<td>25(11)</td>
<td>55(19)</td>
<td>76(16)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thyroid</td>
<td></td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>2(1)</td>
<td>8(4)</td>
<td></td>
</tr>
<tr>
<td>Remaining organs</td>
<td></td>
<td>24(9)</td>
<td>23(12)</td>
<td>26(7)</td>
<td>40(11)</td>
<td>26(10)</td>
<td>11(11)</td>
</tr>
</tbody>
</table>

Results are expressed as mean (SD); n=4.
BIOCHEMISTRY

Urine, plasma, and tissue samples were collected from two animals in each group (see above) and kept frozen at −20°C for analysis of peptide bound label by trichloroacetic acid (TCA) precipitation. Tissue extract was prepared by homogenising 500–1000 mg tissue in 4 ml 0.1 M phosphate buffer, 1% human albumin (Beringwerke, Germany), pH 8.0. Samples (500 ml tissue extract, plasma in dilution 1 + 4, urine in dilution 1 + 249 or 125I-pSP) were counted in a gamma spectrometer (Gambit). Ice cold 20% TCA (1 ml) was added to each sample. The samples were mixed and incubated on ice for 30 minutes. The pellet obtained after centrifugation for 20 minutes at 4°C and 2100 g was counted. The fraction precipitated with TCA was calculated by dividing the counts present in the pellet by the counts present in the sample. The fraction of 125I-pSP precipitated by TCA was 0.94 (mean, n=3).

Results

METABOLISM AND DISTRIBUTION

Table 1 shows the time relations for the distribution of injected radioactivity in the blood, the urinary system, the gastrointestinal tract, and the thyroid gland. After six minutes, 77% of the radioactivity had disappeared from the blood and after 45 minutes only small amounts could be detected. A major part of the peptide—up to 40%—was taken up by the kidneys and excreted in urine. The gastrointestinal tract (stomach, small intestine, caecum, and colon) also accumulated a considerable amount (14%) of the peptide, and the clearance from the gastrointestinal tract was more protracted than from the kidneys. No other tissues seemed to concentrate the peptide. Only small amounts were detected in the liver (0.8%) and the brain (0.01%).

In order to compare the ability of the different tissues to concentrate 125I-pSP, the radioac-
Activity was expressed as a percentage of injected dose per gram tissue (fig 1). The major part of the radioactivity was present in the blood, kidney, and gastrointestinal tract. For a rat weighing about 250 g, the weight of these organs represents approximately 30 g. Thus, after six minutes, 23% of the total radioactivity (table 1) was left for the remaining 220 g of the rat or 0.1% per g tissue. The radioactivity taken up by the kidney was 16% per g tissue or almost 160 times as much as in the remaining tissues. In the gastrointestinal tract, the highest uptake was in the body and pyloric part of the stomach and the duodenum. The uptake in the body of the stomach was 4% per g tissue or 40 times that of the remaining group of tissues. The jejunum, ileum, caecum, and colon also had an increased uptake, as did the uterus and ovaries.

Figure 2 shows the fraction of $^{125}$I-pSP in tissues from the stomach, kidney, plasma, and urine, which could be precipitated by TCA, combined with the variation in radioactivity during the study period. In plasma, the fraction which could be precipitated by TCA gradually decreased to 0.72 after 15 minutes and 0.30 after 240 minutes. In the stomach, most of the radioactivity could also be precipitated after 240 minutes, and the stomach had protracted binding of radioactivity. After 24 hours, the content of radioactivity was still 1% of total radioactivity per gram tissue even though 76% of radioactivity had been excreted in urine. $^{125}$I-pSP seemed only to be metabolised to a minor degree in the urinary system. In the kidney, the fraction of peptide precipitated with TCA hardly decreased, and in urine the main part of the radioactivity could be precipitated, 0.88 after 240 minutes and 0.64 after 24 hours.

When $^{125}$I-pSP (approximately 1 µg) was given together with non-radioactive pSP, there was a dose dependent reduction in the uptake of radioactivity in the body and pyloric part of the stomach and in the kidney (fig 3A). In the various parts of the intestine, there was a reduction only after injection of 10 mg pSP (fig 3B). There was no reduction in uptake in the pancreas, ovaries, or uterus.

**AUTORADIOGRAPHY**

In the kidneys, the label was found to be present in cells of the proximal tubules both at the level of the brush border and in the cytoplasm (fig 4). After two and six minutes, grains were observed only in the first part of the proximal tubule. Later grains were also observed in the first part of the loop of Henle and in cells of some of the collecting tubules of the medulla.

Grains were found in all three parts of the stomach localised almost exclusively in mucus producing cells. In the body, a strong uptake was observed in the neck part of the glands (figs 5A and 6A). Grains were localised mainly in the mucous neck cells, but also in the cytoplasm of some of the parietal cells in the same region (fig 5B). There was no uptake in the surface epithelial cells, the parietal cells, or zymogenic cells in the main part of the glands.
Figure 5 Autoradiographs showing uptake of radioactivity in various parts of the gastrointestinal tract. (A) The mucosa of the body of the stomach 15 minutes after administration of $^{125}$I-pSP. Grains are localised to the neck part of the gastric glands, mainly to the mucous neck cells. (B) Larger magnification of the neck part showing grains also in the parietal cells. (C) The mucosal surface of the body of the stomach 120 minutes after administration of $^{125}$I-pSP. Grains are observed in the lumen of the gastric pits (arrow) and on the luminal surface. (D) The pyloric part of the stomach with grains in the pyloric glands. (E) The duodenum. Grains are localised in Brunner’s glands whereas the epithelium of the crypts in the upper part of the picture is negative. (F) The ileum. Grains are localised to the basal part but also in the cytoplasm of the Paneth cells in the bottom of the crypts of Lieberkühn. (G) The colon. Grains are concentrated in the lower part of the crypts. (H) The pancreas. Part of a large excretory duct with grains in small basal buds of the epithelium. Original magnification: A, ×100; B, ×550; D, ×175; C, E, F, G, H, ×440.
Metabolism of spasmolytic polypeptide in the rat

In the basal buds of the epithelium (fig 5H), it was not possible to localise grains to any particular structures in the ovary or uterus.

In sections of tissues from rats not given \(^{125}\text{I}\)-pSP, there was a little background staining seen as evenly distributed grains with the same intensity within the tissue as outside the tissue and without concentration to any particular structures.

Discussion

In the present study, \(^{125}\text{I}\)-pSP was given intravenously to rats and the metabolism of the peptide and possible target sites in the organs for SP are described. The clearance of \(^{125}\text{I}\)-pSP from blood was slow. When \(^{125}\text{I}\)-epidermal growth factor (EGF) was investigated in a study with the same design, \(^{125}\text{I}\)-EGF was left in blood after two minutes, in comparison with the findings in the present study of 52% of pSP after two minutes and 19% after 15 minutes. The explanation for this difference may be that pSP was not taken up by the liver, which accumulates and degrades the major part of injected EGF. Furthermore, pSP is highly resistant to degradation by proteases and therefore less exposed to enzymatic degradation. This is substantiated by the findings that the percentage of radioactivity which could be precipitated with TCA in the tissues decreased very slowly, and although pSP was taken up by the cells in the proximal tubules of the kidney, the major part of radioactivity excreted in urine could be precipitated with TCA.

The possibility of endocrine effects of SP was suggested recently when it was shown that subcutaneously administered SP is able to protect rats against the development of indomethacin/stress induced gastric ulcerations in a dose of less than 1% of the dosage found to be effective following oral administration. The presence of a receptor has been suggested from in vitro investigations on rat intestinal mucosal cell membranes, and in frozen sections binding of \(^{125}\text{I}\)-ITF was localised to the collecting ducts of the kidney, the neck region, and surface epithelium of the stomach, and to the crypt epithelium of the small intestine and the colon.

Endocrine effects of SP implicate the presence of a cellular receptor localised basolaterally which allows uptake of peptide secreted via the endocrine or paracrine pathways. In the present study, we have used an in vivo model to show binding sites for \(^{125}\text{I}\)-SP. The peptide is distributed via the circulatory system and presented to the basolateral part of the cells. Furthermore, direct binding of radiolabelled peptide to intracellular mucus due to the high affinity of the peptide to the mucin glycoproteins is avoided. Our findings support the assumption that the uptake of \(^{125}\text{I}\)-pSP in the gastrointestinal tract is receptor mediated, as the uptake of radioactivity could be displaced with non-radioactive pSP, with a reduction at the maximum dose to 13% and 28% in the body and the pyloric part of the stomach, respectively, and to approximately 50% in the rest of the intestinal tract.
In the gastrointestinal tract, the radioactivity seemed to be localised primarily in mucus producing cells, which are immunoreactive to SP themselves, namely the mucous neck cells, the cells of the pyloric and cardiac glands, and the duodenal Brunner’s glands. The surface epithelium of the stomach, which produces mucus and the other trefoil peptide, pS2, and the small intestinal goblet cells, which produce ITF, did not bind radioactive pSP. Thus, pSP seems to bind to the same cells that are immunoreactive to the peptide, but not to the cells which are immunoreactive to the other trefoil peptides. The binding seems to be receptor mediated—or at least it can be displaced by excess amounts of unlabelled pSP. The interpretation of these results is not obvious. It may, however, shed new light on the results of Jeffrey et al., who found a discrepancy between localisation of the rat SP in the stomach, determined by immunohistochemistry, and the rat SP mRNA determined by in situ hybridisation. In the body of the stomach, they found the mRNA in the deepest part of the gastric pits, where the immature cells are localised, in contrast to the immunoreactive peptide, which was present in the neighbouring mucous neck cells. In the antrum, the mRNA was found in the deepest part of the pits and in the upper part of the glands, whereas the immunoreactive peptide was present in the deepest part of the glands. It was suggested that the mRNA was present in the immature cells producing the peptide and later when the cells had migrated downwards and developed to mature glandular cells, they still contained the peptide. Another explanation which would fit with both the findings of Jeffrey et al and the findings in the present study of high affinity basolateral uptake of 125I-pSP by the cells which express the peptide immunohistochemically, but not the mRNA at in situ hybridisation, would be that the SP is actually produced in the cells which express the mRNA, and that the peptide is secreted in a paracrine manner basolaterally and thereafter taken up by the mucous neck cells of the body of the stomach and likewise for the mucous glands of the antrum. It would be interesting to investigate whether the other trefoil peptides also bind specifically to the mucus producing cells that are immunoreactive to each particular peptide.

A functional role of the trefoil peptides in the luminal secretions of the gastrointestinal tract seems well established. They are localised to exocrine, most often mucus producing cells. In the lumina, they have been proposed to be involved in oligomerisation processes of the mucin polysaccharide molecules, which lead to formation of gel-like, high viscosity mucus. High concentrations of SP have been measured in rat gastric mucus, and immunoreactive SP has been detected in the mucus layer, and overexpression of pS2 in mice increases the resistance to intestinal damage, whereas mice lacking ITF have impaired defence. In the damaged mucosa, the trefoil peptides have been colocalised with EGF in the recently described “ulcer associated cell lineage.”

The role of the trefoil peptides in the gastrointestinal lumen is further substantiated by the experimental studies showing that intragastrically administered trefoil peptides in a dose dependent manner protect against gastric injury in rats, indicating that orally administered SP is taken up by the mucus layer.

The protective effect of parenterally administered SP might be caused by other mechanisms than an effect related to the mucus layer; for example, an effect on gastric emptying, a growth factor-like effect, stimulation of cell migration, or inhibition of acid secretion (although the latter was investigated with negative results). The autoradiographic findings in the present study, however, suggest an interpretation which might be compatible with the finding of a protective effect of both luminaly and parenterally administered SP. In rats sacrificed within the first 15 minutes after 125I-pSP administration, grains were found only in the mucous neck cells and some of the parietal cells in the body of the stomach. In the rats sacrificed later than that, increasing amounts of grains were also localised in the lumen of the glands, the lumen of the gastric pits, and in the mucus layer. Furthermore, the same phenomenon was observed after 15 minutes, when excess unlabelled SP was given together with 125I-pSP. This was also seen after the dose of 50 µg unlabelled pSP, which is a dose similar to that used by Playford et al to prevent indomethacin induced gastric ulceration. Final conclusions cannot be deduced from the present findings but they suggest receptor mediated uptake of SP and subsequent exocrine secretion, which is unusual for a peptide. The trefoil factors are small peptides with the exceptional property that they are very resistant to degradation by proteases and thereby not exposed to degradation by intracellular enzymes. What could happen in the mucous neck cells (or neighbouring parietal cells) might be compared with the situation in the kidneys. Up to 40% of injected radioactivity is taken up by the kidneys (six minutes), primarily by the proximal tubules. Grains are present in the brush border and cytoplasm indicating that the radioactivity is taken up by the cells. After four hours only 3% is present in the kidneys, 25% is now in the urine, and 88% of this can be precipitated with TCA. Blood accounts for 4%. Thus it seems that the tubular cells of the kidney excrete the major part of the SP without degradation. The intracellular localisation of SP and the possible way of excretion should be studied by autoradiography at the electron microscopical level.

Endogenous trefoil peptides are secreted from the gastric glands and the surface epithelium together with mucus and thereby end up in the most recently secreted inner part of the mucus layer. Injected pSP is taken up by the stomach and if a significant part of the peptide ends up in the mucus layer in the same way as endogenous SP, this might offer an explanation for the mechanism of the protective effect of parenteral SP and also the rather low dosage, in comparison to oral SP, which is necessary to obtain the effect. When SP is given orally, the
luminal side of the mucus layer, which is the part going to be desquamated next, is exposed to the cross linking effect of the SP and possibly only a minor proportion penetrates into the deeper layers.

In conclusion, we have developed a system in the rat whereby circulating SP is targeted to its binding sites and possible sites of action in the gastrointestinal tract. The binding can be displaced by non-radioactive pSP, suggesting the presence of a receptor. This intensifies the need to identify and characterise receptors to the trefoil peptides.

This study was supported by the Biotechnology Centre for Cellular Communication and the Danish Medical Research Coun-

cil. The technical assistance of Jette Schousboe and Jette Hansen, and the photographic assistance of Grezyna Poulsen is warmly acknowledged.

1 Thim L, A new family of growth factor-like peptides. “Tre-
foil” disulfide loop-structures as a common feature in breast cancer associated peptide (pS2), pancreatic spasmolytic polypeptide (PSP) and frog skin peptides (spasmoly-


Distribution and metabolism of intravenously administered trefoil factor 2/porcine spasmolytic polypeptide in the rat

S S Poulsen, J Thulesen, E Nexø and L Thim

Gut 1998 43: 240-247
doi: 10.1136/gut.43.2.240

Updated information and services can be found at:
http://gut.bmj.com/content/43/2/240

These include:

References

This article cites 32 articles, 8 of which you can access for free at:
http://gut.bmj.com/content/43/2/240#BIBL

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

Stomach and duodenum (1689)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/